Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

SurExam Has China Rights to New Ovarian Cancer Test

publication date: Feb 14, 2008

SurExam Life Science & Technology (Shenzhen) Co. has been granted the right to develop a test for early stage ovarian cancer in China that was discovered at Yale School of Medicine. Dr. Jiasen Xu, chief executive officer of SurExam, is a graduate of Yale. The new test uses proteins that the body produces in response to a tumor, along with the tumor proteins, which gives the test the ability to detect both early- and late-stage ovarian cancer with a 99% accuracy. More details...



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital